Xtant Medical shares jump 10.10% premarket after commercial launch of nanOss Strata synthetic bone graft.

Xtant Medical Holdings, Inc. (XTNT) surged 10.10% in premarket trading following the announcement of the commercial launch of its next-generation synthetic bone graft, nanOss Strata. The product, made from hydroxycarbonapatite (HCA), is designed to enhance bioactivity, mimic human bone structure, and improve osteoconductivity, positioning it as a competitive advancement in regenerative medicine. The launch aligns with the company’s strategic focus on orthobiologics innovation and expands its product portfolio, potentially driving revenue growth. Additionally, the news coincided with the company’s recent strong Q3 2025 financial results, including a 19% year-over-year revenue increase, further reinforcing investor optimism. The product’s availability through Xtant’s nationwide distribution network and CEO Sean Browne’s emphasis on innovation underscored the significance of the development, directly supporting the sharp premarket price rise.